首页> 美国卫生研究院文献>PLoS Clinical Trials >Alpha conotoxin-BuIA globular isomer is a competitive antagonist for oleoyl-L-alpha-lysophosphatidic acid binding to LPAR6; A molecular dynamics study
【2h】

Alpha conotoxin-BuIA globular isomer is a competitive antagonist for oleoyl-L-alpha-lysophosphatidic acid binding to LPAR6; A molecular dynamics study

机译:α-芋螺毒素-BuIA球状异构体是油酰基-L-α-溶血磷脂酸与LPAR6结合的竞争性拮抗剂;分子动力学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Lysophosphatidic acid receptor 6 (LPAR6) is a G-protein coupled receptor (GPCR) involved in hair development and cytoskeleton formation in mammals. Its proliferation is implicated in several forms of cancer including liver cancer, squamous cell carcinoma and metastatic prostate cancer. Current study emphasizes the isolation of competitive non-lipid and stable peptide antagonists for Lysophosphatidic acid ligand. A total of 148 conotoxin structures were characterized for their binding abilities against LPAR6. Subsequently, top 10 conotoxins were selected on the basis of binding energy values, residual contributions and conformational cluster saturations. BuIA (a member of Alpha- conotoxins family), contryphan-R and contryphan-Lo (Synthetic class) conotoxins, exhibiting efficient binding parameters were subjected to molecular dynamics simulation assays and topology analysis. We propose that BuIA might be a potent antagonist due to its predominant binding at the extracellular region of LPAR6. Current study provides a backbone for understanding structural and functional insights of LPAR6 and findings of this study may be helpful in designing novel therapeutic targets for the treatment of cancers caused by elevated LPAR6 expression.
机译:溶血磷脂酸受体6(LPAR6)是一种G蛋白偶联受体(GPCR),参与哺乳动物的头发发育和细胞骨架形成。其增殖与多种形式的癌症有关,包括肝癌,鳞状细胞癌和转移性前列腺癌。当前的研究强调针对溶血磷脂酸配体的竞争性非脂质和稳定肽拮抗剂的分离。表征共148个芋螺毒素结构对LPAR6的结合能力。随后,根据结合能值,残留贡献和构象簇饱和度选择了前十种芋螺毒素。表现出有效结合参数的BuIA(α-芋螺毒素家族的成员),contryphan-R和contryphan-Lo(合成类)螺毒素被进行了分子动力学模拟分析和拓扑分析。我们提出,由于BuIA在LPAR6的细胞外区域占优势,因此可能是一种有效的拮抗剂。当前的研究为理解LPAR6的结构和功能见解提供了基础,这项研究的发现可能有助于设计新的治疗靶标,以治疗由LPAR6表达升高引起的癌症。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号